Academic Journal
Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism-A Systematic Review and Meta-Analysis.
| Τίτλος: | Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism-A Systematic Review and Meta-Analysis. |
|---|---|
| Συγγραφείς: | Huijben M; Department of Urology, University Medical Centre Utrecht, Utrecht, the Netherlands., Prinsen A; Department of Urology, University Medical Centre Utrecht, Utrecht, the Netherlands., de Kort L; Department of Urology, University Medical Centre Utrecht, Utrecht, the Netherlands., van Breda J; Department of Urology, University Medical Centre Utrecht, Utrecht, the Netherlands. |
| Πηγή: | Andrology [Andrology] 2026 Oct; Vol. 14 (7), pp. 1971-1987. Date of Electronic Publication: 2026 Apr 16. |
| Τύπος έκδοσης: | Journal Article; Systematic Review; Meta-Analysis |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101585129 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-2927 (Electronic) Linking ISSN: 20472919 NLM ISO Abbreviation: Andrology Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Wiley-Blackwell, 2013- |
| Ιατρικοί όροι (MeSH): | Hypogonadism*/drug therapy , Hypogonadism*/complications , Gonadotropins*/therapeutic use , Spermatogenesis*/drug effects , Fertility*/drug effects , Infertility, Male*/drug therapy , Infertility, Male*/etiology , Azoospermia*/drug therapy, Humans ; Male ; Female ; Pregnancy ; Pregnancy Rate |
| Περίληψη: | Background: Male hypogonadotropic hypogonadism typically presents with azoospermia and is one of the few causes of infertility amenable to a medical intervention. Gonadotropin therapy offers a chance to restore spermatogenesis and fertility in these individuals. Therefore, this study aims to determine the efficacy of gonadotropins in inducing spermatogenesis and achieving pregnancies in males with hypogonadotropic hypogonadism and azoospermia. Additionally, the time needed to induce spermatogenesis and pregnancy, and potential predictors associated with better outcomes, were evaluated. Methods: A systematic literature search was conducted in the Medline, Embase, and Cochrane databases till May 16, 2025. Clinical studies, including randomized control trials, cohort studies, and case-control studies, using gonadotropins as a treatment for hypogonadotropic hypogonadism and assessing sperm induction or pregnancy outcomes, were eligible for inclusion. Primary outcomes included sperm parameters (appearance, concentration, motility, morphology, time needed to induce spermatogenesis) and pregnancy outcomes (pregnancy rate, proportion of naturally achieved pregnancies, proportion of live births, and time to conception). The methodological quality and risk of bias were assessed using the Effective Public Health Practice Project quality assessment tool for quantitative studies, and showed that most included studies were of poor methodological quality. Results: A total of 50 studies were included from 2351 identified articles, treating 1583 male patients with hypogonadotropic hypogonadism and azoospermia. The pooled success rate of spermatogenesis induction was 74% (95% confidence interval: 66%-82%), with a mean time to spermatogenesis of 11.8 months. The overall pregnancy rate among couples with a child wish was 52% (95% confidence interval: 42%-62%), with a mean time to pregnancy from the start of treatment of 19 months. Mean post-treatment sperm concentration was 9.8 million/mL (95% confidence interval 8.6-11.0), and spontaneous pregnancies also occurred with suboptimal sperm parameters. Gonadotropin dual therapy was more effective than human chorionic gonadotropin monotherapy. Conclusion: Gonadotropin therapy, particularly combined gonadotropin treatment, is effective in restoring spermatogenesis and achieving pregnancy in men with hypogonadotropic hypogonadism. While sperm quality often remains below normal thresholds, natural conception is frequently achieved. These findings support the use of combined gonadotropin therapy as the first-line approach for fertility induction in this population. Trial Registration: This review was registered on PROSPERO under the registration number CRD4202232149. A review protocol was not previously published. (© 2026 The Author(s). Andrology published by John Wiley & Sons Ltd on behalf of American Society of Andrology and European Academy of Andrology.) |
| References: | J Paediatr Child Health. 2024 Feb-Mar;60(2-3):53-57. (PMID: 38572627) BMC Med Res Methodol. 2014 Dec 19;14:135. (PMID: 25524443) J Assist Reprod Genet. 2021 Apr;38(4):803-807. (PMID: 33432424) Clin Endocrinol (Oxf). 1994 Jul;41(1):57-63. (PMID: 7914153) J Clin Endocrinol Metab. 1988 Jun;66(6):1144-51. (PMID: 3372679) Endocr Rev. 2019 Apr 1;40(2):669-710. (PMID: 30698671) Fertil Steril. 2006 Dec;86(6):1664-8. (PMID: 17007848) Hum Fertil (Camb). 2009 Dec;12(4):204-8. (PMID: 19824804) J Eval Clin Pract. 2012 Feb;18(1):12-8. (PMID: 20698919) Asian J Androl. 2019 Nov-Dec;21(6):623-627. (PMID: 31062720) J Assist Reprod Genet. 2021 Oct;38(10):2601-2608. (PMID: 33982169) Reprod Biomed Online. 2007 Aug;15(2):156-60. (PMID: 17697490) Medicine (Baltimore). 2019 Aug;98(31):e16616. (PMID: 31374027) Urologia. 2021 Feb;88(1):50-55. (PMID: 31622170) Contemp Clin Trials. 2015 Nov;45(Pt A):139-45. (PMID: 26343745) Clin Endocrinol (Oxf). 2017 Jan;86(1):75-87. (PMID: 27467188) Eur J Endocrinol. 1994 Oct;131(4):347-54. (PMID: 7921222) Int Urol Nephrol. 1996;28(3):367-74. (PMID: 8899478) Hum Reprod. 1999 Jun;14(6):1540-5. (PMID: 10357972) J Urol. 2005 Jun;173(6):2072-5. (PMID: 15879837) Stat Methods Med Res. 2018 Jun;27(6):1785-1805. (PMID: 27683581) Curr Pharm Des. 2021;27(24):2775-2783. (PMID: 32445446) Eur J Endocrinol. 1998 Sep;139(3):298-303. (PMID: 9758439) Fertil Steril. 1991 Aug;56(2):319-24. (PMID: 1906410) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Eur Urol. 2021 Sep;80(3):333-357. (PMID: 34183196) J Endocrinol Invest. 2006 Sep;29(8):706-13. (PMID: 17033259) Andrologia. 2016 Jun;48(5):601-2. (PMID: 26341841) Pituitary. 2021 Jun;24(3):326-333. (PMID: 33226541) Fertil Steril. 2018 Dec;110(7):1239-1245. (PMID: 30503112) Eur J Endocrinol. 2024 Jan 3;190(1):S1-S11. (PMID: 38128110) J Clin Med. 2025 Jul 05;14(13):. (PMID: 40649142) Andrology. 2016 Jan;4(1):87-94. (PMID: 26779870) Reprod Biol Endocrinol. 2017 Mar 7;15(1):17. (PMID: 28270212) Ann N Y Acad Sci. 2024 Oct;1540(1):133-146. (PMID: 39190467) Am J Mens Health. 2019 Jan-Feb;13(1):1557988318818280. (PMID: 30569789) Int J Androl. 1994 Oct;17(5):241-7. (PMID: 7698849) J Androl. 2009 Nov-Dec;30(6):679-84. (PMID: 19478332) Andrology. 2023 Sep;11(6):987-996. (PMID: 36680549) Lancet. 2014 Apr 5;383(9924):1250-63. (PMID: 24119423) Int Urol Nephrol. 2012 Apr;44(2):393-9. (PMID: 21989858) Fertil Steril. 2002 Feb;77(2):270-3. (PMID: 11821082) Int J Endocrinol. 2019 Dec 18;2019:6743489. (PMID: 31929795) Clin Endocrinol (Oxf). 2025 Feb;102(2):167-177. (PMID: 39445789) Hum Fertil (Camb). 2010;13(2):83-9. (PMID: 20196691) Andrology. 2026 Oct;14(7):1971-1987. (PMID: 41987691) Clin Endocrinol (Oxf). 1993 Feb;38(2):203-8. (PMID: 8435901) J Sex Med. 2020 Apr;17(4):645-657. (PMID: 32171629) Health Promot Int. 2005 Dec;20(4):367-74. (PMID: 16169885) Life (Basel). 2021 Dec 09;11(12):. (PMID: 34947899) N Engl J Med. 1985 Sep 12;313(11):651-5. (PMID: 3927163) Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):236-42. (PMID: 22385118) J Clin Endocrinol Metab. 1985 Oct;61(4):746-52. (PMID: 3928676) Int J Androl. 2005 Aug;28(4):202-7. (PMID: 16048631) J Clin Endocrinol Metab. 2013 May;98(5):1781-8. (PMID: 23650335) J Clin Endocrinol Metab. 2015 Jun;100(6):2449-55. (PMID: 25825944) Andrology. 2014 Nov;2(6):794-808. (PMID: 25271205) Pituitary. 2010 Jun;13(2):105-10. (PMID: 19838805) Fertil Steril. 1991 Dec;56(6):1143-50. (PMID: 1743335) J Clin Endocrinol Metab. 1993 Dec;77(6):1545-9. (PMID: 8263139) J Clin Endocrinol Metab. 2009 Mar;94(3):801-8. (PMID: 19066302) Hum Reprod. 1997 May;12(5):980-6. (PMID: 9194651) J Endocrinol Invest. 2010 Oct;33(9):618-23. (PMID: 20436264) Aust N Z J Obstet Gynaecol. 2012 Jun;52(3):293-8. (PMID: 22694078) J Urol. 2024 Dec;212(6):789-799. (PMID: 39145501) Fertil Steril. 2009 Aug;92(2):594-604. (PMID: 18930225) Medicine (Baltimore). 2016 Mar;95(9):e2867. (PMID: 26945370) Fertil Steril. 1998 Aug;70(2):256-62. (PMID: 9696217) Urology. 2013 Dec;82(6):1291-5. (PMID: 24094652) Int J Androl. 1999 Jun;22(3):184-9. (PMID: 10367239) J Androl. 2003 Jul-Aug;24(4):604-11. (PMID: 12826700) J Clin Endocrinol Metab. 1988 Dec;67(6):1140-5. (PMID: 3142911) Fertil Steril. 2009 Sep;92(3):979-990. (PMID: 18930190) Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):91-103. (PMID: 25617175) Endocr Pract. 2024 Oct;30(10):978-986. (PMID: 39025301) Hum Reprod. 2008 May;23(5):1029-34. (PMID: 18343809) J Endocrinol Invest. 2021 Nov;44(11):2445-2454. (PMID: 33738751) Clin Endocrinol (Oxf). 2018 Dec;89(6):712-718. (PMID: 30194850) Arch Androl. 2004 Jul-Aug;50(4):267-71. (PMID: 15277005) Int J Mol Sci. 2020 Dec 22;22(1):. (PMID: 33375030) Fertil Steril. 2012 Oct;98(4):836-42. (PMID: 22763096) |
| Contributed Indexing: | Keywords: azoospermia; gonadotropins; male fertility; male hypogonadotropic hypogonadism; pregnancy; spermatogenesis |
| Substance Nomenclature: | 0 (Gonadotropins) |
| Entry Date(s): | Date Created: 20260416 Date Completed: 20260921 Latest Revision: 20260924 |
| Update Code: | 20260924 |
| PubMed Central ID: | PMC13592061 |
| DOI: | 10.1111/andr.70226 |
| PMID: | 41987691 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!